InfuSystem Holdings, Inc. (NYSE:INFU) CEO Richard Dilorio Sells 5,398 Shares

InfuSystem Holdings, Inc. (NYSE:INFU) CEO Richard Dilorio sold 5,398 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $8.87, for a total value of $47,880.26. Following the completion of the transaction, the chief executive officer now directly owns 416,659 shares in the company, valued at approximately $3,695,765.33. This trade represents a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Richard Dilorio also recently made the following trade(s):

• On Monday, November 25th, Richard Dilorio sold 20,000 shares of InfuSystem stock. The shares were sold at an average price of $9.32, for a total value of $186,400.00.

InfuSystem Price Performance

Shares of NYSE:INFU traded down $0.10 during trading on Wednesday, reaching $8.85. 39,965 shares of the stock were exchanged, compared to its average volume of 60,063. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. InfuSystem Holdings, Inc. has a 1-year low of $5.74 and a 1-year high of $10.99. The stock has a fifty day moving average price of $7.29. The stock has a market capitalization of $188.15 million, a price-to-earnings ratio of 147.52 and a beta of 1.45.

Hedge Funds Weigh In On InfuSystem

A number of institutional investors have recently modified their holdings of INFU. Vanguard Group Inc. raised its position in shares of InfuSystem by 1.7% during the first quarter. Vanguard Group Inc. now owns 1,083,730 shares of the company’s stock worth $9,288,000 after purchasing an additional 18,432 shares during the period. Sequoia Financial Advisors LLC acquired a new position in shares of InfuSystem during the second quarter worth approximately $272,000. ARS Investment Partners LLC raised its position in shares of InfuSystem by 11.4% during the second quarter. ARS Investment Partners LLC now owns 33,510 shares of the company’s stock worth $229,000 after purchasing an additional 3,422 shares during the period. Bank of New York Mellon Corp grew its holdings in InfuSystem by 6.1% during the second quarter. Bank of New York Mellon Corp now owns 93,899 shares of the company’s stock worth $641,000 after buying an additional 5,391 shares in the last quarter. Finally, Panagora Asset Management Inc. bought a new stake in InfuSystem during the second quarter worth $208,000. 71.13% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. B. Riley assumed coverage on InfuSystem in a research note on Thursday, September 26th. They issued a “buy” rating and a $13.00 price target on the stock. StockNews.com raised InfuSystem from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 8th.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.